openPR Logo
Press release

5 Key Upshots from Fact.MR’s Report on Fibrosarcoma Market for Forecast Period 2017 - 2026

01-22-2021 07:01 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: Fact.MR

Fibrosarcoma Market

Fibrosarcoma Market

Fibrosarcoma has no definite cause like other sarcomas. However, most of the sarcomas are associated with the genetic mutations. Soft tissue fibrosarcoma is among rare cancer which has no exact cause but carries various risk factors. Undergoing as radiotherapy to treat other cancer is one of the factors that is increasing the risk of fibrosarcoma. Currently, there are very few ways to treat fibrosarcoma with complications involved. Hence, researchers and research institutes around the world are researching for some very effective treatments. Targeted therapies are also being focused on to treat fibrosarcoma. There are also many anti-angiogenesis agents under development and few are in clinical trials.
Chemotherapy for soft tissue sarcoma usually involves a combination of various drugs. Hence, companies are researching on new drugs effective in treating soft tissue sarcoma.

Request a report sample to gain comprehensive market insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=353

According to a study by Fact.MR, the global fibrosarcoma market is expected to witness steady growth. The market is likely to register CAGR of 5.5% during the forecast period 2017-2026. The global fibrosarcoma market is also projected to bring in US$ 442.4 million revenue. Fibrosarcoma is increasingly rare as a diagnosis compared to other sarcoma subtypes. Some of the sarcomas are sensitive to chemotherapy, hence ongoing attempts are being done to intensify chemotherapy. However, fibrosarcoma that does not respond to chemotherapy, needs to be treated with other methods but might lead to some side-effects. This is driving the development of new therapies with potential benefits. Below insights show how the global fibrosarcoma market will perform in the coming years.

5 Forecast Highlights on Global Fibrosarcoma Market

• North America is expected to remain dominant in the global fibrosarcoma market during the forecast period 2017-2026. Well-developed healthcare infrastructure in North America is one of the factors boosting the growth of fibrosarcoma treatment in the region. Technological advancement is also resulting in the development of advanced cancer treatment drugs. Moreover, increasing population suffering from diabetes, overweight and depression are also leading towards high possibilities of cancer.

For information on the Research Approach used in the Report, Request Methodology@ https://www.factmr.com/connectus/sample?flag=RM&rep_id=353
• Europe and Asia Pacific Excluding Japan (APEJ) are also expected to witness growth in the diagnoses and treatment of fibrosarcoma due to the increasing investments in the research and development activities for treatment of various cancers.
• Chemotherapy is expected to be the most preferred treatment for fibrosarcoma. By the end of 2026, chemotherapy is projected to reach close to US$ 200 million revenue.
• Hospitals are expected to be the largest end-users in the global fibrosarcoma market. Hospitals are projected to reach nearly US$ 200 million revenue by the end of 2026.
• Among various distribution channels, hospital pharmacy is expected to emerge as the largest distribution channel during the forecast period 2017-2026. Accounting for nearly half of the revenue share, hospital pharmacies are projected to exceed US$ 100 million revenue towards the end of 2026.

Get Full Access of the Report @ https://www.factmr.com/checkout/353/S

The report also offers an in-depth analysis of the leading market players in the global market for fibrosarcoma, which will remain active through 2026. These include companies such as Johnson & Johnson, Pfizer Inc., Eli Lilly and Company, Baxter International Inc., Novartis AG, Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Limited, Bristol-Myers Squibb Company, Celon Laboratories Limited, and Cadila Pharmaceuticals Limited.

Unit No: AU-01-H
Gold Tower (AU)
Plot No: JLT-PH1-I3A
Jumeirah Lakes Towers, Dubai
United Arab Emirates
Contact: +353-1-6111-593
E-mail: sales@factmr.com
Website : https://www.factmr.com

About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports.
We believe transformative intelligence can educate and inspire businesses to make smarter decisions.
We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release 5 Key Upshots from Fact.MR’s Report on Fibrosarcoma Market for Forecast Period 2017 - 2026 here

News-ID: 2229428 • Views:

More Releases from Fact.MR

Elevators Market to Grow at 11% CAGR, Reaching $270 Billion by 2033
Elevators Market to Grow at 11% CAGR, Reaching $270 Billion by 2033
The international elevators market (エレベーター市場) got to an evaluation of United States $ 95 billion in 2023 as well as is predicted to get to United States $ 270 billion by the end of 2033. This market is anticipated to expand at a substantial CAGR of 11% from 2023 to 2033. The elevators market stands as a crucial cog in the wheel of contemporary facilities, promoting upright mobility in significantly metropolitan
Stone Paper Market Explosive Growth CAGR of 8.0% to Reach $2,096.9 Million by 2033
Stone Paper Market Explosive Growth CAGR of 8.0% to Reach $2,096.9 Million by 20 …
The international stone paper market (ストーンペーパーマーケット) is forecasted to get to an assessment of United States $ 972.6 million by the end of 2023 and also is anticipated to expand at a CAGR of 8.0% to get to United States $ 2,096.9 million by the end of 2033. The stone paper market is experiencing considerable development possibilities driven by raising need from the product packaging as well as publishing markets. Customer
Foliar Fertilizers Market Predicts 4% CAGR, $344 Million Expansion by 2029
Foliar Fertilizers Market Predicts 4% CAGR, $344 Million Expansion by 2029
The worldwide foliar fertilizers market is forecasted to accomplish a 4% ordinary substance yearly development price (CAGR) by the verdict of the projection duration. This development is anticipated to produce an increment chance of United States$ 344 million by the end of 2029. Foliar plant foods supply an useful choice for supplying nutrients to plants as they can be straight related to the fallen leaves. This approach not just improves nutrient
E-Compass Market $11.9 Billion Discovery By 2033 | Fact.MR
E-Compass Market $11.9 Billion Discovery By 2033 | Fact.MR
In 2023, the global E-Compass Market reached a valuation of US$ 2.6 billion, and projections indicate a substantial growth trajectory, with estimates soaring to US$ 11.9 billion by 2033. 𝗚𝗲𝘁 𝗙𝗿𝗲𝗲 𝗦𝗮𝗺𝗽𝗹𝗲 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝗽𝘆: https://www.factmr.com/connectus/sample?flag=S&rep_id=8417 This remarkable surge in market value is attributed to the anticipated surge in worldwide electronic compass sales, expected to surge at an impressive Compound Annual Growth Rate (CAGR) of 16.5% over the coming decade. The eCompass, an electric

All 5 Releases


More Releases for Fibrosarcoma

07-21-2021 | Health & Medicine
Fact.MR
Fibrosarcoma Market to Expand at a Healthy CAGR of 5.5% through 2031
Fibrosarcoma has no definite cause like other sarcomas. However, most of the sarcomas are associated with the genetic mutations. Soft tissue fibrosarcoma is among rare cancer which has no exact cause but carries various risk factors. Undergoing as radiotherapy to treat other cancer is one of the factors that is increasing the risk of fibrosarcoma. This report works as a rich source of information for key entities such as policy makers,
04-19-2018 | Health & Medicine
Fact.MR
Fibrosarcoma Market: Hospital Pharmacies to Generate Significant Revenues Throug …
Undertaking radiotherapy for the treatment of malignant tumor has led to prevalence of fibrosarcoma among cancer patients. Fibrosarcoma is a rare malignant tumor that is generally treated by conducting radiation treatments and chemotherapy. As there are very few treatment procedures for fibrosarcoma, research and healthcare institutions are investing in research and development to develop effective treatment techniques. In addition, leading research institutes are focusing on developing targeted therapies that targets
03-05-2018 | Health & Medicine
Fact.MR
Fibrosarcoma Market Assessment by Products, Drug Profile forecast for 2017-2026
A fresh study, covering “Fibrosarcoma Market Assessment by Products, Drug Profile forecast for 2017-2026” has been broadcasted to wide online repository of Fact MR, which presents deep focus on the Healthcare Market. This smart study contains precise data that offers a clear insight about market current scenario and future projections for the benefit of readers. Moreover, the study enclosed significant data which tends to make the research a powerful source
Fibrosarcoma - Pipeline Review, H1 2018 by MarketResearchReports.biz
"The Report Fibrosarcoma - Pipeline Review, H1 2018 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Fibrosarcoma Market Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosarcoma - Pipeline Review, H1 2018, provides an overview of the Fibrosarcoma (Oncology) pipeline landscape. Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/1581047 Fibrosarcoma is a malignant tumor derived from fibrous connective tissue.
Fibrosarcoma treatment Market Estimated To Flourish By 2025
Sarcoma is referred to as a type of cancer that originates from the mesenchymal transformed cells. Fibrosarcoma is a rare malignancy, which is characterized by anaplastic undifferentiated spindle cells or proliferating immature fibroblasts in a storiform appearance. The disease arises from the fibrous tissue of bones such as the tibia, the femur, or the mandible. The tumor may be categorized based on differentiation degree into low-grade malignancy, intermediate malignancy, and
Fibrosarcoma - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Fibrosarcoma - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosarcoma - Pipeline Review, H2 2017, provides an overview of the Fibrosarcoma (Oncology) pipeline landscape. Fibrosarcoma is a malignant tumor derived from fibrous connective tissue. Symptoms include local pain, local swelling, local warmth, dilated blood vessels pain